TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Bioxcel Therapeutics ( (BTAI) ) is now available.
On October 14, 2025, BioXcel Therapeutics announced positive results from a correlation study related to the SERENITY At Home trial, which will be included in a supplemental New Drug Application submission planned for early 2026. The study demonstrated a strong correlation between clinician assessments and patient or caregiver-rated outcomes using the modified CGI-S scale, supporting its use for evaluating BXCL501 in outpatient settings, with no serious adverse events reported.
The most recent analyst rating on (BTAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.
Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing innovative treatments for neurological and psychiatric disorders. The company is known for its work on BXCL501, a sublingual film for acute agitation associated with schizophrenia and bipolar disorder.
Average Trading Volume: 9,782,314
Technical Sentiment Signal: Sell
Current Market Cap: $49.9M
For a thorough assessment of BTAI stock, go to TipRanks’ Stock Analysis page.